Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 15;47(12):e999–e1007. doi: 10.1097/CCM.0000000000004042

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 2. — Biomarker kinetics of [TIMP-2] × [IGFBP7] over time and suPAR at baseline. A, Biomarker kinetics in relation to maximum acute kidney injury (AKI) stage within 7 d: AKI 0/1 = no or mild AKI, AKI 2/3 = moderate or severe AKI without the need for RRT, RRT = AKI with the need for RRT. B, Biomarker kinetics in relation to AKI course, comparing AKI stage at day 1 and day 7: stable AKI 0/1 = stable AKI 0/1 within 7 d, AKI 0/1 to 2/3 = AKI progression form AKI 0/1 to AKI 2/3, AKI 2/3 to 0/1 = recovery from AKI 2/3 to AKI 0/1, stable AKI 2/3 = stable AKI 2/3 within 7 d, RRT = AKI progression with need for RRT. ^aFor [TIMP-2] × [IGFBP7] measurement, three urinary samples were missing for 12 hr, two for 24 hr, and six for 48 hr in non-RRT patients, and one sample for 48 hr in the RRT group (anuria, ongoing surgery, administration of toluidine blue/interference with the urinary immunoassay). ^bPatient with the fulfillment of RRT criteria earlier than 12 hr, 24 hr, and 48 hr were excluded from the respective analysis of [TIMP-2] × [IGFBP7] values at the corresponding time points (six patients < 12 hr, eight patients < 24 hr, 11 patients ≤ 48 hr). RRT = renal replacement therapy, suPAR = soluble urokinase-type plasminogen activator receptor, [TIMP-2] × [IGFBP7] = product of tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7. Boldface values indicate p < 0.05.